Skip to main content

Research Repository

Advanced Search

Bioactivity of a compound derived from Amaryllidaceae (Daffodil) in a C.elegans model of obesity

People Involved

Project Description

A previous proof-of-concept study demonstrated that an alkaloid extracted from daffodil bulbs by Agroceutical Products Ltd (APL), alongside sustainable galanthamine production (alkaloid used for Alzheimer’s disease management), selectively reduced release of two important antioxidant and anti-inflammatory molecules from cells exposed to high-levels of glucose. These molecules are typically associated with obesity and metabolic syndrome and are implicated in the development of cardiovascular disease.

This project will further explore the properties of this daffodil-derived alkaloid extracted from bulbs grown by Grampian Growers Ltd (GG) and APL, using the APL extraction process, in a whole-organism model of obesity (C. elegans nematode). The information gathered will not only expand the evidence-base to support investment in the refinement of the process to isolate different alkaloids, in addition to galanthamine, but will also provide GG with the opportunity to develop a business case to expand their production stream and maximise their products’ commercial potential

Status Project Complete
Funder(s) Industrial Biotechnology Innovation Centre
Value £9,994.00
Project Dates Sep 1, 2023 - May 30, 2024

You might also like

A human Glutathione Peroxidase 4 3 untranslated region knock-in mouse model to study susceptibility to colon cancer in obesity Apr 1, 2017 - Dec 31, 2021
Colorectal cancer (CRC) incidence is rising steadily and in parallel with increasing prevalence of obesity in Scotland. Recent data indicate that the highest incidence rates are in the North East. The increasing prevalence of obes... Read More about A human Glutathione Peroxidase 4 3 untranslated region knock-in mouse model to study susceptibility to colon cancer in obesity.

The in vitro effect of natural products and anti-cancer agents: targeting the efflux transporter ABCG2 Jul 1, 2017 - Dec 31, 2019
Medicinal use of natural products, such as, extracts from plants have existed for many years particularly in China and are now widely available around the world. Several different types of cancer including breast cancer are becoming insensitive and r... Read More about The in vitro effect of natural products and anti-cancer agents: targeting the efflux transporter ABCG2.